148 related articles for article (PubMed ID: 3098444)
1. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
Broggini M; Rossi C; Colombo T; D'Incalci M
Cancer Treat Rep; 1982 Jan; 66(1):127-33. PubMed ID: 6796267
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Rutty CJ; Judson IR; Abel G; Goddard PM; Newell DR; Harrap KR
Cancer Chemother Pharmacol; 1986; 17(3):251-8. PubMed ID: 3091280
[TBL] [Abstract][Full Text] [Related]
4. N-(Hydroxymethyl) melamines.
Coley HM
Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
[TBL] [Abstract][Full Text] [Related]
5. Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
Judson IR; Rutty CJ; Abel G; Graham MA
Br J Cancer; 1986 May; 53(5):601-6. PubMed ID: 3087399
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of hexamethylmelamine on human tumor xenografts serially transplanted in nude mice.
Kubota T; Tanino H; Watanabe M; Kitajima M
Anticancer Res; 1994; 14(6B):2521-4. PubMed ID: 7872676
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice.
Broggini M; Colombo T; D'Incalci M; Donnelli MG; Gescher A; Garattini S
Cancer Treat Rep; 1981; 65(7-8):669-72. PubMed ID: 6788370
[TBL] [Abstract][Full Text] [Related]
9. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
10. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
[TBL] [Abstract][Full Text] [Related]
11. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
12. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
13. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Stehman FB; Ehrlich CE; Callangan MF
Gynecol Oncol; 1984 Feb; 17(2):189-95. PubMed ID: 6423460
[TBL] [Abstract][Full Text] [Related]
14. Hexamethylmelamine as a single second-line agent in ovarian cancer.
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Gynecol Oncol; 1990 Jan; 36(1):93-6. PubMed ID: 2104819
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts.
Tanino H; Kubota T; Yamada Y; Koh J; Kase S; Furukawa T; Kuo TH; Saikawa Y; Kitajima M; Naito Y
Jpn J Cancer Res; 1995 Aug; 86(8):770-5. PubMed ID: 7559101
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
Manetta A; MacNeill C; Lyter JA; Scheffler B; Podczaski ES; Larson JE; Schein P
Cancer Treat Rev; 1991 Mar; 18 Suppl A():23-9. PubMed ID: 1904305
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of trimelamol in refractory ovarian cancer.
Judson IR; Calvert AH; Gore ME; Balmanno K; Gumbrell LA; Perren T; Wiltshaw E
Br J Cancer; 1991 Feb; 63(2):311-3. PubMed ID: 1997112
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Wharton JT; Rutledge F; Smith JP; Herson J; Hodge MP
Am J Obstet Gynecol; 1979 Apr; 133(7):833-44. PubMed ID: 219695
[TBL] [Abstract][Full Text] [Related]
20. Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine.
Connors TA; Cumber AJ; Ross WC; Clarke SA; Mitchley BC
Cancer Treat Rep; 1977 Aug; 61(5):927-8. PubMed ID: 408005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
